JonathanWadeGoldmanMD

Oncology • Santa Monica, CA

Physician

Join to view full profile

Dr. Goldman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Goldman's full profile

Already have an account?

Office
2020 Santa Monica Blvd
Ste 600
Santa Monica, CA 90404
Phone+1 310-633-8400

Fax+1 310-633-8419

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
University of California (San Francisco)Residency, Internal Medicine, 2001 - 2004
Stanford University School of MedicineClass of 2001

Certifications & Licensure

CA State Medical License 2003 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
COMPLETED
PHASE1, PHASE2
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients Start of enrollment: 2013 Nov 01
Completed
Phase 1, Phase 2
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer Start of enrollment: 2014 Jun 01
Terminated
Phase 2
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
ACTIVE_NOT_RECRUITING
PHASE3
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC Start of enrollment: 2017 Jun 29
Terminated
Phase 2
Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer Start of enrollment: 2021 Jan 29
Active, not recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Study of RYZ101 in Combination with SoC in Subjects with SSTR+ ES-SCLC Start of enrollment: 2022 Oct 10
RECRUITING
PHASE1
Roles: Contact
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) Start of enrollment: 2023 Sep 13
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

A plain language summary of results from the FLAURA2 study: Initial (first-line) osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mut...
David Planchard, Pasi A Jänne, Ying Cheng, James Chih-Hsin Yang, Noriko Yanagitani
Future Oncology. 2025-04-01
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.
Roy S Herbst, Thomas John, Christian Grohé, Jonathan W Goldman, Terufumi Kato
Nature Medicine. 2025-03-17
1 citations
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2025-03-01

Lectures

A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Safety and antitumor activity of durvalumab monotherapy in patients with pretreated extensive disease small-cell lung cancer (ED-SCLC).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

High-Dose Radiotherapy with Chemotherapy Effective in Treating People with Non-Small Cell Lung CancerJanuary 11th, 2024
Many Patients with NSCLC Receive Immunotherapy ‘Indefinitely’ – Are They Benefiting?September 18th, 2023
CASPIAN Trial Update: Phase 3 Results & PerspectivesJune 23rd, 2020
Join now to see all

JonathanWadeGoldmanMD

Dr. Goldman is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.